We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alnylam Pharmaceuticals announced that a year-long phase 3 trial of its drug patisiran showed that the therapy met both its major objectives in patients with transthyretin-mediated amyloidosis (ATTR) with cardiomyopathy, improving patients’ ability to walk and increasing their quality of life. Read More
The combination of Merck’s blockbuster anti-PD-1 therapy Keytruda and Eisai’s Lenvima failed to show superiority to the standard of care of Lenvima alone as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Read More
Gilead Sciences’ Biktarvy, a three-component antiviral, suppressed HIV infections in 99 percent of patients who took it as part of two phase 3 studies. There were no treatment failures, the company reported at the 24th International AIDS Conference in Montreal. Read More
After less than stellar interim results from a phase 3 trial focused on head and neck cancer, AstraZeneca is calling it quits in the indication for the checkpoint inhibitor it netted following its now four-year-old partnership with Innate Pharma. Read More
Massachusetts-based Editas Medicine announced that the FDA has removed a partial clinical hold on its trial of EDIT-301 (AsCas12a), its experimental gene treatment for severe sickle cell disease. Read More
Bristol Myers Squibb’s (BMS) combination treatment for renal cell cancer missed its primary endpoint of disease-free survival in the phase 3 CheckMate-914 trial, Part A, the company reported. Read More
Seagen and Astellas Pharma are touting positive topline data from an early study of Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda as a treatment for patients with unresectable locally advanced or metastatic urothelial cancer who can’t receive cisplatin treatment. Read More
Novartis no longer plans to submit PD-1 checkpoint inhibitor tislelizumab for approval in the U.S. as a monotherapy for nonsmall-cell lung cancer (NSCLC). Read More
In a worrying sign for several drug candidates, Roche said it has halted five phase 1 and 2 trials evaluating therapies for major diseases including cancers, asthma and a metabolic disorder. Read More